Related Experiment Videos
Therapy of ulcerative colitis.
Stephen B Hanauer1, Miles Sparrow
1Department of Medicine and the Section of Gastroenterology and Nutrition, University of Chicago, Chicago, Illinois, USA. shanauer@medicine.bsd.uchicago.edu
Current Opinion in Gastroenterology
|February 11, 2005
Summary
Recent ulcerative colitis (UC) research highlights ongoing debates in aminosalicylate use and advances in biologic therapies. Probiotics are now established for pouchitis prevention post-surgery.
Area of Science:
- Gastroenterology
- Internal Medicine
- Clinical Therapeutics
Background:
- Ulcerative colitis (UC) treatment involves ongoing controversies and emerging clinical advancements.
- Gastroenterologists require updated information on UC management strategies.
Purpose of the Study:
- To review recent developments in ulcerative colitis treatment.
- To emphasize advances nearing clinical practice adoption.
Main Methods:
- Literature review of recent studies and clinical trials in ulcerative colitis.
- Focus on therapies with potential for clinical integration.
Main Results:
- Aminosalicylate formulations and dosing remain controversial.
- Biologic therapies are being explored for UC, with anti-tumor necrosis factor (TNF) therapy benefits under evaluation.
- Calcineurin inhibitors and probiotic therapy for pouchitis show promise.
Conclusions:
- Optimal dosing and delivery of fundamental UC therapies require further research.
- New biologic agents targeting pro-inflammatory cytokines are under investigation.
- Leukocyte apheresis trials are ongoing for severe UC.